Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Review of tenofovir-emtricitabine

Authors Saba Woldemichael Masho, Cun-Lin Wang, Daniel E Nixon

Published 15 January 2008 Volume 2007:3(6) Pages 1097—1104

Saba Woldemichael Masho1, Cun-Lin Wang2, Daniel E Nixon3
1Department of Epidemiology and Community Health, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA; 2Federal Drug Administration, Bethesda, Maryland, USA; 3Virginia Commonwealth University HIV/AIDS Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Abstract: Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.
Keywords: tenofovir, emtricitabine, Truvada, TDF, FTC, antiretroviral agent

Download Article [PDF] 

Readers of this article also read:

Assessment of the risk of falling with the use of timed up and go test in the elderly with lower extremity osteoarthritis

Zasadzka E, Borowicz AM, Roszak M, Pawlaczyk M

Clinical Interventions in Aging 2015, 10:1289-1298

Published Date: 7 August 2015

Effects of size and surface of zinc oxide and aluminum-doped zinc oxide nanoparticles on cell viability inferred by proteomic analyses

Pan CH, Liu WT, Bien MY, Lin IC, Hsiao TC, Ma CM, Lai CH, Chen MC, Chuang KJ, Chuang HC

International Journal of Nanomedicine 2014, 9:3631-3643

Published Date: 2 August 2014

Quality of life in elderly patients following coronary artery bypass grafting

Bak E, Marcisz C

Patient Preference and Adherence 2014, 8:289-299

Published Date: 14 March 2014

US perspective on gluten-related diseases

Leonard MM, Vasagar B

Clinical and Experimental Gastroenterology 2014, 7:25-37

Published Date: 24 January 2014

The influence of sex, race, and age on pain assessment and treatment decisions using virtual human technology: a cross-national comparison

Torres CA, Bartley EJ, Wandner LD, Alqudah AF, Hirsh AT, Robinson ME

Journal of Pain Research 2013, 6:577-588

Published Date: 22 July 2013

The protective effects of cerium oxide nanoparticles against hepatic oxidative damage induced by monocrotaline

Kamal A Amin, Mohamed S Hassan, El-Said T Awad, et al

International Journal of Nanomedicine 2011, 6:143-149

Published Date: 17 January 2011

Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank

Rune Erichsen, Timothy L Lash, Stephen J Hamilton-Dutoit, et al

Clinical Epidemiology 2010, 2:51-56

Published Date: 30 March 2010

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter

Therapeutics and Clinical Risk Management 2008, 4:1371-1374

Published Date: 5 December 2008